Obesity Drugs Show Early Promise Against PMOS

Charlotte Touzalin, a 18-year-old college student from Colorado, faced weight gain, abnormal periods, and facial hair growth - symptoms that also troubled her mother, Anne Schultz, for years without any diagnosis. Both were finally identified with polyendocrine metabolic ovarian syndrome (PMOS), a hormonal disorder affecting 1 in 8 women.

Unlike Schultz, Touzalin began her young adulthood on a hopeful note after participating in a study testing GLP-1 obesity medications. Research indicates these drugs may help PMOS by promoting weight loss, improving insulin resistance, hormone balance, and ovulation. Melanie Cree, an endocrinologist leading the study, found these medications to be effective in treating PMOS, leading to weight loss, normalized insulin and testosterone levels, and regular periods in participating women.

Despite promising results, access to these drugs remains a challenge due to lack of approval for PMOS and insurance barriers. Touzalin had to discontinue her GLP-1 treatment due to financial constraints, while Schultz continues to fight with her insurer to secure coverage for her daughter.